Physician profile
Bruce M Berkowitz
NPI 1275634982
$557.68
in general payments reported to CMS, 2019-2025
14 companies · $17.38 in 2025
The $17.38 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.90 · 2020: $17.87 · 2021: $57.57 · 2022: $72.67 · 2023: $239 · 2024: $138 · 2025: $17.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.29 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $89.23 | 2020-2023 | Xarelto |
| Exact Sciences Corporation | $74.20 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $58.67 | 2023-2024 | Mounjaro |
| Mylan Specialty L.P. | $54.62 | 2022 | |
| Lundbeck LLC | $54.50 | 2024 | Rexulti |
| Amgen INC. | $47.47 | 2023-2024 | Otezla, Repatha |
| Insmed, INC. | $34.79 | 2024-2025 | Brinsupri, Arikayce |
| Baxter Healthcare | $31.70 | 2023 | Hillrom - Life 2000 Ventilation System |
| Sumitomo Pharma America, INC. | $28.69 | 2023 | Gemtesa |
| Novo Nordisk INC | $21.32 | 2023 | Rybelsus |
| Inogen, INC. | $18.05 | 2022 | |
| Boston Scientific Corporation | $17.98 | 2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.